The UK and US have signed a significant trade agreement that will preserve no levies on UK medicine products entering the American market.
The Terms of the Accord
As part of the deal, the UK has agreed to raise spending on drugs through the public health system. This pledge secures that duties on these key goods will be held at zero for a duration of the next three years.
This development comes after previous statements to significantly raise duties on patented drug products, with potential rates mentioned as high as one hundred percent.
"This agreement with the UK bolsters the international landscape for innovative medicines and brings much-needed equity to American-British drug exports," a statement said.
Trade Impact
Medicines are one of the Britain's biggest exports to the US, which is easily the primary market for large UK drugmakers.
Trade data indicate that in the one-year period to the end of the third quarter, the UK sold medicines totaling billions to the US. This figure represented 17.4% of British export trade in that timeframe.
"This deal safeguards employment, stimulates investment and facilitates the UK to emerge as a worldwide center for medical research," the Business and Trade Secretary stated.
Detailed NHS Changes
The pact includes several notable pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it considers new treatments to be prohibitively costly by 25%.
- Increased NHS Spending: There is a aim to raise total public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Refund Ceiling: The percentage pharmaceutical firms must return to the NHS to stay within budget will be restricted at fifteen percent. Previously, rebates were more than twenty percent.
Broader Context
This agreement takes place against a ongoing row between the sector and the ministers over spending levels and approval rates.
This friction were exacerbated by claims that American consumers were paying significantly more for the same drugs than people in the UK and Europe.
In recent months, several major drug company projects in the UK have been paused or cancelled, while major funding commitments have been pledged toward US facilities.
The Science Minister acknowledged that the NHS must invest a greater share on drugs, noting that its budget allocation on drugs had declined as a percentage of its total funding over the past decade.
